Daiichi Sankyo said Aug 10 it and Innovent Biologics have signed an exclusive entrusted promotion agreement for Vifutai (quizartinib hydrochloride tablets) in mainland China. Under the deal, Daiichi Sankyo will be responsible for clinical development

2026-08-10

Daiichi Sankyo said Aug 10 it and Innovent Biologics have signed an exclusive entrusted promotion agreement for Vifutai (quizartinib hydrochloride tablets) in mainland China. Under the deal, Daiichi Sankyo will be responsible for clinical development, manufacturing and supply, while Innovent obtains exclusive rights to promote and will lead commercialization in the China market.

Other News
2026-08-10

According to Israel's Channel 12, Nikolai Mladenov, the senior representative of the Gaza Peace Committee, discussed the roadmap for Gaza disarmament and the gradual withdrawal of Israeli troops in an interview. This came shortly after Israeli Prime

2026-08-10

Yemen's Deputy Defense Minister: The Houthi rebels' systematic attacks on civilian targets are targeting the people.